EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial

Phil McEwan, Jason A Davis, Peter D Gabb, David C Wheeler, Peter Rossing iD, Glenn M Chertow, Ricardo Correa-Rotter, Kouichi Tamura iD, Salvatore Barone, Juan Jose Garcia Sanchez

Clinical Kidney Journal · 01.02.2024 · 17 (2)

DOI: 10.1093/ckj/sfae025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 09.02.2024. Verfasst von Phil McEwan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics and Outcomes Research Ltd, Cardiff, UK. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial enrolled patients with estimated glomerular filtration rate 25–75 mL/min/1.73 m2 and urine albumin-to-creatinine ratio >200 mg/g. The Dapagliflozin Effect on CardiovascuLAR Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial enrolled patients with type 2 diabetes, a higher range of kidney function and no albuminuria criterion. The study objective was to estimate the cost-effectiveness of dapagliflozin in a broad chronic kidney disease population based on these two trials in the UK, Spain, Italy and Japan.

Methods

We adapted a published Markov model based on the DAPA-CKD trial but to a broader population, irrespective of urine albumin-to-creatinine ratio, using patient-level data from the DAPA-CKD and DECLARE-TIMI 58 trials. We sourced cost and utility inputs from literature and the DAPA-CKD trial. The analysis considered healthcare system perspectives over a lifetime horizon.

Results

Treatment with dapagliflozin was predicted to attenuate disease progression and extend projected life expectancy by 0.64 years (12.5 versus 11.9 years, undiscounted) in the UK, with similar estimates in other settings. Clinical benefits translated to mean quality-adjusted life year (QALY; discounted) gains between 0.45 and 0.68 years across countries. Incremental cost-effectiveness ratios in the UK, Spain, Italy and Japan ($10 676/QALY, $14 479/QALY, $7771/QALY and $13 723/QALY, respectively) were cost-effective at country-specific willingness-to-pay thresholds. Subgroup analyses suggest dapagliflozin is cost-effective irrespective of urinary albumin-to-creatine ratio and type 2 diabetes status.

Conclusion

Treatment with dapagliflozin may be cost-effective for patients across a wider spectrum of estimated glomerular filtration rates and albuminuria than previously demonstrated, with or without type 2 diabetes, in the UK, Spanish, Italian and Japanese healthcare systems.

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitoralbuminuriachronic kidney diseasecost-effectivenessdapagliflozin

Autor:innen und Institutionen

  • Health Economics and Outcomes Research Ltd, Cardiff, UK.
  • Department of Renal Medicine, University College London, London, UK.
  • Steno Diabetes Centre Copenhagen, Herlev, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Departments of Medicine and Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Nephrology and Mineral Metabolism, National Medical Science and Nutrition Institute Salvador Zubiran, Mexico City, Mexico.

ORCID-Profile: Peter Rossing, Kouichi Tamura

Förderung

  • AstraZeneca

Zitieren

APA

McEwan, P., Davis, J. A., Gabb, P. D., Wheeler, D. C., Rossing, P., Chertow, G. M., Correa-Rotter, R., Tamura, K., Barone, S., & Garcia Sanchez, J. J. (2024). Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial. Clinical Kidney Journal, 17(2). https://doi.org/10.1093/ckj/sfae025

Vancouver

McEwan P, Davis JA, Gabb PD, Wheeler DC, Rossing P, Chertow GM, et al. Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial. Clinical Kidney Journal. 2024;17(2). doi:10.1093/ckj/sfae025

BibTeX
@article{McEwan2024,
  author = {McEwan, Phil and Davis, Jason A and Gabb, Peter D and Wheeler, David C and Rossing, Peter and Chertow, Glenn M and Correa-Rotter, Ricardo and Tamura, Kouichi and Barone, Salvatore and Garcia Sanchez, Juan Jose},
  title = {Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial},
  journal = {Clinical Kidney Journal},
  year = {2024},
  volume = {17},
  number = {2},
  doi = {10.1093/ckj/sfae025}
}
Kostenlos starten →